| dc.contributor.author | RAHAJENG, BANGUNAWATI | |
| dc.contributor.author | IKAWATI, ZULLIES | |
| dc.contributor.author | ANDAYANI, TRI MURTI | |
| dc.contributor.author | DWIPRAHASTO, IWAN | |
| dc.date.accessioned | 2018-05-31T03:14:45Z | |
| dc.date.available | 2018-05-31T03:14:45Z | |
| dc.date.issued | 2018-05-05 | |
| dc.identifier.issn | 0974-2441 | |
| dc.identifier.uri | http://repository.umy.ac.id/handle/123456789/19248 | |
| dc.description.abstract | Objective:. In Indonesia, carbamazepine was approved by The National Agency of Drugs And Foods Controls for the prophylaxis of lithium unresponsive
manic-depressive disorders, all types of epilepsy (except for petit mal), and trigeminal neuralgia. This study was conducted to determine the off-label
use of carbamazepine in Indonesia.
Methods: This research is a nonexperimental descriptive study with a cross-sectional method. Data collection retrospectively by taking all patients that
were prescribed carbamazepine in 2014. Data were obtained from four general hospitals in Yogyakarta. The off-label use of carbamazepine was defined a
prescribing of carbamazepine outside the indication that approved by The National Agency for Drugs And Foods Controls of Republic of Indonesia (NA-DFC).
Results: The use of carbamazepine in 2014 were 704 prescriptions, and on 251 (35.6%) of them were off-label drug use. The off-label use of
carbamazepine were 149 prescriptions (59.4%) for neuropathic pain, 83 prescriptions (33.0%) for nociceptive pain, and 19 prescriptions (7.6%) for
other indications.
Conclusion: The mostly off-label use of carbamazepine in Indonesia was in neuropathic pain with low evidence. Further research to study the efficacy
and the risk of off-label use of carbamazepine may be an essential step toward defining the potential for such purpose. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Innovare Academic Journal | en_US |
| dc.subject | anticonvulsant, carbamazepine, prescription, off-label, neuropathic pain | en_US |
| dc.title | THE OFF- LABEL USE OF CARBAMAZEPINE IN INDONESIA | en_US |
| dc.type | Article | en_US |
